Recent Updates
Recently added Catalysts

Control vaccine with the adjuvant system.

Phase 2

Tuberculosis | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 19, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment147
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00707967Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.PHASE2 COMPLETED 37Jun 30, 2008May 27, 2009Aug 24, 20181 Switzerland
NCT00397943Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy AdultsPHASE2 COMPLETED 110Nov 15, 2006Dec 1, 2009Jun 19, 20191 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Solicited Local Symptoms
During the 7-day period (Days 0-6) post vaccination following each dose

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed.

Number of Subjects With Solicited General Symptoms
During the 7-day period (Days 0-6) post vaccination following each dose

Assessed solicited general symptoms were fatigue, temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], gastrointestinal symptoms (gastro) \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.

Number of Subjects With Unsolicited Adverse Events (AEs)
During the 30-day period (Days 0-29) post vaccination

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Number of Subjects With Serious Adverse Events (SAEs)
During the entire study period, from Day 0 up to Day 210

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity

Number of Subjects With Normal Biochemical and Haematological Levels
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], creatinine \[CREA\], eosinophil \[EOS\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Normal Haematological Levels
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were haematocrit \[Hct\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Biochemical and Haematological Levels Below Normal
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], creatinine \[CREA\], eosinophil \[EOS\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Haematological Levels Below Normal
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were haematocrit \[Hct\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Biochemical and Haematological Levels Above Normal
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], creatinine \[CREA\], eosinophil \[EOS\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Haematological Levels Above Normal
At Day 0, 7, 30, 37 and 60

Among biochemical and haematological parameters assessed were haematocrit \[Hct\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.

Number of Subjects With Any and Grade 3 Solicited Local Symptoms
During the 7-day (Days 0-6) follow-up period after each vaccine dose and across doses

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
During the 7-day (Days 0-6) follow-up period after each vaccine dose and across doses

Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as causally related to the study vaccination.

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
During the 30-day (Days 0-29) follow-up period after each vaccine dose

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Number of Subjects With SAEs
From Month 2 up to Month 12

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Number of Subjects With Normal or Abnormal Haematological and Biochemical Levels
At Day 0

Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.

Number of Subjects With Normal and Abnormal Haematological and Biochemical Levels
At Day 7

Among haematological and biochemical parameters assessed were Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Basophils, Creatinine, Eosinophils, Haemoglobin, Haematocrite, Lymphocytes, Monocytes, Neutrophils, Platelets, Red blood cells (RBC), White blood cells (WBC). Inside = within laboratory reference range; Above = above laboratory reference range; Below = below laboratory reference range.

Levels of C-reactive Protein
At Day 0

The levels of C-reactive protein are expressed in milligram per deciliter (mg/dL).

Levels of Immunoglobulin E
At Day 0

The levels of Immunoglobulin E are expressed in 1000 units per liter (1000 U/L).

Secondary Endpoints
Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines
At Day 0, 30, 60 and 210
Frequency of M72 Specific CD4/8+ T Cells Expressing at Least One Cytokine and Another Signal Molecule
At Day 0, 30, 60 and 210
Cell Count of CD4+ T Cells
At Day 0, 30, 60 and 210
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group AEXPERIMENTALSubjects receiving the candidate vaccine
Group BPLACEBO_COMPARATORSubjects receiving the adjuvant
Group CPLACEBO_COMPARATORSubjects receiving physiological saline
M72/AS01B GroupEXPERIMENTALHealthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
M72/AS02A GroupEXPERIMENTALHealthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
Mtb72F/AS02A GroupACTIVE_COMPARATORHealthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
Non-adjuvanted GroupACTIVE_COMPARATORHealthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
Control GroupPLACEBO_COMPARATORHealthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
Interventions
NameTypeDescription
GSK's candidate Mycobacterium tuberculosis vaccine 692342BIOLOGICALIntramuscular injection, 2 doses at 0, 1 month
Control vaccine with the adjuvant system.BIOLOGICALIntramuscular injection, 2 doses at 0, 1 month
Control vaccine with physiological salineBIOLOGICALIntramuscular injection, 2 doses at 0, 1 month
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant systemBIOLOGICALIntramuscular injection, 2 doses at 0, 1 month
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological salineBIOLOGICALIntramuscular injection, 2 doses at 0, 1 month
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subjects who the Investigator believes that they can and will comply with the requirements of the protocol. * A male or female between, and including, 18 and 50 years of age at the time of the first vaccination. * Written informed consent obtained from the subject prior to any...

Countries:SwitzerlandBelgium
Unlock Eligibility Criteria
Competitive Landscape -Tuberculosis 7 trials